Given that everolimus showed antitumor activity in preclinical models of pancreatic cancer and breast cancer metastasis33, we inferred that everolimus may be a therapeutic agent for WSB2/mTOR axis-mediated HCC progression. This evidence concerns the gene WSB2 and breast cancer.